- Centers & Specialties
- Medical Education
- PhD, Cambridge University
- MD, University of Edinburgh
- Residency, St. Mary's Hospital
- Fellowship, Brigham and Women's Hospital|Fellowship, Dana Farber Cancer Institute
- Boston: Massachusetts General Hospital
- Insurances Accepted
- Aetna Health Inc.
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- Cigna (PAL #'s)
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - ACD
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Medicare - ACD
- Neighborhood Health Plan - ACD
- Neighborhood Health Plan - PBO
- OSW - Connecticut
- OSW - Maine
- OSW - New Hampshire
- OSW - Rhode Island
- OSW - Vermont
- Private Health Care Systems (PHCS)
- Railroad Medicare
- Railroad Medicare - ACD
- Senior Whole Health
- Tufts Health Plan
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
- Patient Age Group
A consortium of academic and industry organizations led by a team from the MGH Vaccine and Immunotherapy Center has launched a new effort to develop an entirely new type of vaccine against Q fever.
An approach developed by MGH investigators may provide a solution to the limitations that have kept pancreatic islet transplantation from meeting its promise as a cure for type 1 diabetes.
Inspired by his wife's memory, Jeffrey Gelfand, MD, and his MGH colleagues set out to create a vaccine to attack tumors in patients already diagnosed with cancer.
A novel approach to cancer immunotherapy may provide a cost-effective weapon against some of the most deadly tumors, including ovarian cancer and mesothelioma. A protein engineered by MGH investigators to combine a molecule targeting a tumor antigen with an immune-function stimuating protein prolonged survival in animal models of both tumors.
New research indicates that using a particular laser to pre-treat the site of a flu shot may boost the body's immune response against influenza.
Pretreating the site of intradermal vaccination – vaccine delivered into the skin rather than to muscles beneath the skin – with a particular wavelength of laser light may substantially improve vaccine effectiveness without the adverse effects of chemical additives currently used to boost vaccine efficacy.
The Vaccine and Immunotherapy Center at the MGH (VIC), has joined with 24 other institutions as part of the first-ever JDRF Encapsulation Consortium in the fight against type 1 diabetes.
The Vaccine and Immunotherapy Center at Massachusetts General Hospital (VIC), has joined with 24 other institutions as part of the first-ever JDRF Encapsulation Consortium in the fight against type 1 diabetes
The Vaccine & Immunotherapy Center (VIC) at the MGH is committed to projects that accelerate vaccine and immunotherapy development, including those dedicated to finding improved treatment options for people with Type 1 diabetes, an autoimmune disease in which a person's pancreas stops producing insulin.
A newly created consortium plans to change the future of vaccine research.
MGH Hotline 1.23.09 The MGH is a hub of scientific research and discovery, but translating these breakthroughs into commercial applications can be a challenging and sometimes confusing process.
An introduction to the Medicine Innovation Program
The Medicine Innovation Program grants supports and provides opportunities to advance innovations in health care delivery within the Department of Medicine at Massachusetts General Hospital.
55 Fruit Street
Boston MA, 02114-2696
Phone 1: 617-726-3906